Molecular insights of the G2019S substitution in LRRK2 kinase domain associated with Parkinson's disease: A molecular dynamics simulation approach

被引:30
作者
Agrahari, Ashish Kumar [1 ]
Doss, George Priya C. [1 ]
Siva, R. [1 ]
Magesh, R. [2 ]
Zayed, Hatem [3 ]
机构
[1] VIT, Sch Biosci & Technol, Dept Integrat Biol, Vellore 632014, Tamil Nadu, India
[2] DU, SRIHER, Dept Biotechnol, Chennai 600116, Tamil Nadu, India
[3] Qatar Univ, Coll Hlth & Sci, Dept Biomed Sci, Doha, Qatar
关键词
PD; LRRK2; Kinase domain; G2019S; DYG; Molecular dynamics simulation; MUTATIONAL ANALYSIS; PROTEIN; IMPACT; MECHANISMS; GENE; GTPASE; MODEL;
D O I
10.1016/j.jtbi.2019.03.003
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The G2019S substitution in the Leucine-rich repeat kinase 2 (LRRK2) is significantly associated with Parkinson's disease (PD). This substitution was identified in both familial and sporadic forms of PD with a higher frequency. Few computational studies have reported the impact of G2019S substitution on inhibitors of the kinase domain of LRRK2. However, no computational study deeply investigated the possible impact of the G2019S substitution on the kinase domain in its Apo conformation. Therefore, in this study, we used 200 ns molecular dynamic simulation using the GROMACS 5.1.4 package software to investigate the impact of the G2019S substitution on the structure of the kinase domain of LRRK2. Our results indicate that the G2019S substitution affects the dynamics and stability of LRRK2 by decreasing the flexibility and increasing the compactness of the kinase domain and showing its tendency to be in an active conformation for long time interval because of the high energy barrier between active and inactive conformation. This study predicts the molecular pathogenicity mechanism of the G2019S on patients with PD and provides a potential platform for developing therapeutics for patients with PD that harbor this amino acid substitution. (C) 2019 Elsevier Ltd. All rights reserved.
引用
收藏
页码:163 / 171
页数:9
相关论文
共 50 条
  • [31] LRRK2 G2019S and R1441G mutations associated with Parkinson's disease are common in the Basque Country, but relative prevalence is determined by ethnicity
    Gorostidi, A.
    Ruiz-Martinez, J.
    Lopez de Munain, A.
    Alzualde, A.
    Masso, J. F. Marti
    NEUROGENETICS, 2009, 10 (02) : 157 - 159
  • [32] The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites
    Greggio, Elisa
    Taymans, Jean-Marc
    Zhen, Eugene Yuejun
    Ryder, John
    Vancraenenbroeck, Renee
    Beilina, Alexandra
    Sun, Peng
    Deng, Junpeng
    Jaffe, Howard
    Baekelandt, Veerle
    Merchant, Kalpana
    Cookson, Mark R.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 389 (03) : 449 - 454
  • [33] Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans
    Lesage, Suzanne
    Patin, Etienne
    Condroyer, Christel
    Leutenegger, Anne-Louise
    Lohmann, Ebba
    Giladi, Nir
    Bar-Shira, Anat
    Belarbi, Soraya
    Hecham, Nassima
    Pollak, Pierre
    Ouvrard-Hernandez, Anne-Marie
    Bardien, Soraya
    Carr, Jonathan
    Benhassine, Traki
    Tomiyama, Hiroyuki
    Pirkevi, Caroline
    Hamadouche, Tarik
    Cazeneuve, Cecile
    Basak, A. Nazli
    Hattori, Nobutaka
    Duerr, Alexandra
    Tazir, Meriem
    Orr-Urtreger, Avi
    Quintana-Murci, Lluis
    Brice, Alexis
    HUMAN MOLECULAR GENETICS, 2010, 19 (10) : 1998 - 2004
  • [34] Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson ' s disease
    Senchuk, Megan M.
    Van Raamsdonk, Jeremy M.
    Moore, Darren J.
    NEUROBIOLOGY OF DISEASE, 2021, 151
  • [35] Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease
    Greggio, Elisa
    BIOCHEMICAL SOCIETY TRANSACTIONS, 2012, 40 : 1058 - 1062
  • [36] Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD
    Poulopoulos, Markos
    Cortes, Etty
    Vonsattel, Jean-Paul G.
    Fahn, Stanley
    Waters, Cheryl
    Cote, Lucien J.
    Moskowitz, Carol
    Honig, Lawrence S.
    Clark, Lorraine N.
    Marder, Karen S.
    Alcalay, Roy N.
    JOURNAL OF MOLECULAR NEUROSCIENCE, 2012, 47 (01) : 139 - 143
  • [37] Development of LRRK2 Kinase Inhibitors for Parkinson's Disease
    Galatsis, Paul
    Henderson, Jaclyn
    Kormos, Bethany L.
    Hirst, Warren D.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 49, 2014, 49 : 43 - 58
  • [38] Fluctuation Imaging of LRRK2 Reveals that the G2019S Mutation Alters Spatial and Membrane Dynamics
    Sanstrum, Bethany J.
    Goo, Brandee M. S. S.
    Holden, Diana Z. Y.
    Delgado, Donovan D.
    Nguyen, Thien P. N.
    Lee, Kiana D.
    James, Nicholas G.
    MOLECULES, 2020, 25 (11):
  • [39] Parkinson's disease-associated mutations in the GTPase domain of LRRK2 impair its nucleotide-dependent conformational dynamics
    Wu, Chun-Xiang
    Liao, Jingling
    Park, Yangshin
    Reed, Xylena
    Engel, Victoria A.
    Hoang, Neo C.
    Takagi, Yuichiro
    Johnson, Steven M.
    Wang, Mu
    Federici, Mark
    Nichols, R. Jeremy
    Sanishvili, Ruslan
    Cookson, Mark R.
    Hoang, Quyen Q.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2019, 294 (15) : 5907 - 5913
  • [40] Olfactory identification in LRRK2 G2019S mutation carriers: a relevant marker?
    Saunders-Pullman, Rachel
    Mirelman, Anat
    Wang, Cuiling
    Alcalay, Roy N.
    Luciano, Marta San
    Ortega, Robert
    Raymond, Deborah
    Mejia-Santana, Helen
    Ozelius, Laurie
    Clark, Lorraine
    Orr-Utreger, Avi
    Marder, Karen
    Giladi, Nir
    Bressman, Susan B.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2014, 1 (09): : 670 - 678